244 related articles for article (PubMed ID: 22035519)
1. Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs.
Kuang Y; Balakrishnan K; Gandhi V; Peng X
J Am Chem Soc; 2011 Dec; 133(48):19278-81. PubMed ID: 22035519
[TBL] [Abstract][Full Text] [Related]
2. ROS-inducible DNA cross-linking agent as a new anticancer prodrug building block.
Cao S; Wang Y; Peng X
Chemistry; 2012 Mar; 18(13):3850-4. PubMed ID: 22378607
[No Abstract] [Full Text] [Related]
3. Photo-triggered fluorescent theranostic prodrugs as DNA alkylating agents for mechlorethamine release and spatiotemporal monitoring.
Cao Y; Pan R; Xuan W; Wei Y; Liu K; Zhou J; Wang W
Org Biomol Chem; 2015 Jun; 13(24):6742-8. PubMed ID: 25997534
[TBL] [Abstract][Full Text] [Related]
4. Influence of phosphate and phosphoesters on the decomposition pathway of 1,2-bis(methylsulfonyl)-1-(2-chloroethyhydrazine (90CE), the active anticancer moiety generated by Laromustine, KS119, and KS119W.
Penketh PG; Shyam K; Zhu R; Baumann RP; Ishiguro K; Sartorelli AC
Chem Res Toxicol; 2014 May; 27(5):818-33. PubMed ID: 24618018
[TBL] [Abstract][Full Text] [Related]
5. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes.
Chen W; Balakrishnan K; Kuang Y; Han Y; Fu M; Gandhi V; Peng X
J Med Chem; 2014 Jun; 57(11):4498-510. PubMed ID: 24801734
[TBL] [Abstract][Full Text] [Related]
7. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
Peng X; Gandhi V
Ther Deliv; 2012 Jul; 3(7):823-33. PubMed ID: 22900465
[TBL] [Abstract][Full Text] [Related]
8. Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells.
Wang Y; Fan H; Balakrishnan K; Lin Z; Cao S; Chen W; Fan Y; Guthrie QA; Sun H; Teske KA; Gandhi V; Arnold LA; Peng X
Eur J Med Chem; 2017 Jun; 133():197-207. PubMed ID: 28388522
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological studies of the thiols-triggered anticancer prodrug for a more effective cancer therapy.
Xu Y; Chen J; Li Y; Peng S; Gu X; Sun M; Gao K; Fang J
Org Biomol Chem; 2015 Mar; 13(9):2634-9. PubMed ID: 25581090
[TBL] [Abstract][Full Text] [Related]
10. Aromatic nitrogen mustard-based prodrugs: activity, selectivity, and the mechanism of DNA cross-linking.
Chen W; Han Y; Peng X
Chemistry; 2014 Jun; 20(24):7410-8. PubMed ID: 24806710
[TBL] [Abstract][Full Text] [Related]
11. Reduced Toxicity of Liposomal Nitrogen Mustard Prodrug Formulation Activated by an Intracellular ROS Feedback Mechanism in Hematological Neoplasm Models.
Lin M; Guo W; Zhang Z; Zhou Y; Chen J; Wang T; Zhong X; Lu Y; Yang Q; Wei Q; Han M; Xu D; Gao J
Mol Pharm; 2020 Feb; 17(2):499-506. PubMed ID: 31825633
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents.
Chen W; Fan H; Balakrishnan K; Wang Y; Sun H; Fan Y; Gandhi V; Arnold LA; Peng X
J Med Chem; 2018 Oct; 61(20):9132-9145. PubMed ID: 30247905
[TBL] [Abstract][Full Text] [Related]
13. p-(Methylsulfinyl)phenyl nitrogen mustard as a novel bioreductive prodrug selective against hypoxic tumors.
Kwon CH; Blanco DR; Baturay N
J Med Chem; 1992 May; 35(11):2137-9. PubMed ID: 1597864
[No Abstract] [Full Text] [Related]
14. Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress.
McGivern TJP; Slator C; Kellett A; Marmion CJ
Mol Pharm; 2018 Nov; 15(11):5058-5071. PubMed ID: 30192548
[TBL] [Abstract][Full Text] [Related]
15. A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).
Miller ML; Shizuka M; Wilhelm A; Salomon P; Reid EE; Lanieri L; Sikka S; Maloney EK; Harvey L; Qiu Q; Archer KE; Bai C; Vitharana D; Harris L; Singh R; Ponte JF; Yoder NC; Kovtun Y; Lai KC; Ab O; Pinkas J; Keating TA; Chari RVJ
Mol Cancer Ther; 2018 Mar; 17(3):650-660. PubMed ID: 29440292
[TBL] [Abstract][Full Text] [Related]
16.
Reshetnikov V; Özkan HG; Daum S; Janko C; Alexiou C; Sauer C; Heinrich MR; Mokhir A
Molecules; 2020 May; 25(11):. PubMed ID: 32486084
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.
Tercel M; Yang S; Atwell GJ; Smith E; Gu Y; Anderson RF; Denny WA; Wilson WR; Pruijn FB
Bioorg Med Chem; 2010 Jul; 18(14):4997-5006. PubMed ID: 20580559
[TBL] [Abstract][Full Text] [Related]
18. A New Cross-Link for an Old Cross-Linking Drug: The Nitrogen Mustard Anticancer Agent Mechlorethamine Generates Cross-Links Derived from Abasic Sites in Addition to the Expected Drug-Bridged Cross-Links.
Nejad MI; Johnson KM; Price NE; Gates KS
Biochemistry; 2016 Dec; 55(50):7033-7041. PubMed ID: 27992994
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Chen L; Waxman DJ
Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and analysis of activity of a potential anti-melanoma prodrug with a hydrazine linker.
Frąckowiak-Wojtasek B; Gąsowska-Bajger B; Mazurek M; Raniszewska A; Logghe M; Smolarczyk R; Cichoń T; Szala S; Wojtasek H
Eur J Med Chem; 2014 Jan; 71():98-104. PubMed ID: 24287558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
